Literature DB >> 15135415

Rapid purification of truncated tau proteins: model approach to purification of functionally active fragments of disordered proteins, implication for neurodegenerative diseases.

Natalia Csokova1, Rostislav Skrabana, Hans-Dieter Liebig, Anna Mederlyova, Peter Kontsek, Michal Novak.   

Abstract

Truncated tau is of great interest because of its important role in neurofibrillary pathogenesis in Alzheimer's disease (AD). A major obstacle for characterization of detailed biochemical and biological properties of truncated tau species and their fragments has been the lack of reliable and quick purification methods. Uneven distribution of acidic and basic residues in tau determines that the N- and C-terminal tau fragments require entirely different purification conditions. Conventional methods take several days; they do not allow purification of the acidic N-terminal tau fragments and do not prevent aggregation during purification that makes purified truncated tau unusable in functional studies. To prevent these inherent problems, we have designed a two-step, highly efficient purification procedure yielding a fully functional, non-aggregated homogeneous population of truncated tau molecules. Various forms of tau produced in bacteria without the need for a heat pre-treatment step were subjected to anion- and cation-exchange chromatography. Conditions were developed that allowed effective separation and purification of acidic and/or basic tau species. Following the gel filtration step, up to 10mg of tau proteins with 96% purity was obtained within one working day. Purified truncated tau exhibited an unmodified immunoreactivity and allowed its functional activity analysis. Since many neurodegenerative diseases have implicated similar disordered proteins in their pathogenesis, our procedure will allow their detailed analysis and characterization.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15135415     DOI: 10.1016/j.pep.2004.01.012

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  12 in total

1.  Understanding the kinetic roles of the inducer heparin and of rod-like protofibrils during amyloid fibril formation by Tau protein.

Authors:  Gayathri Ramachandran; Jayant B Udgaonkar
Journal:  J Biol Chem       Date:  2011-09-19       Impact factor: 5.157

2.  Cortical and hippocampal neurons from truncated tau transgenic rat express multiple markers of neurodegeneration.

Authors:  Peter Filipcik; Martin Cente; Gabriela Krajciova; Ivo Vanicky; Michal Novak
Journal:  Cell Mol Neurobiol       Date:  2009-03-05       Impact factor: 5.046

3.  Plasma Leptin Reflects Progression of Neurofibrillary Pathology in Animal Model of Tauopathy.

Authors:  Martin Cente; Stefan Zorad; Tomas Smolek; Lubica Fialova; Natalia Paulenka Ivanovova; Katarina Krskova; Lucia Balazova; Rostislav Skrabana; Peter Filipcik
Journal:  Cell Mol Neurobiol       Date:  2020-09-30       Impact factor: 5.046

4.  A Method for Systematic Assessment of Intrinsically Disordered Protein Regions by NMR.

Authors:  Natsuko Goda; Kana Shimizu; Yohta Kuwahara; Takeshi Tenno; Tamotsu Noguchi; Takahisa Ikegami; Motonori Ota; Hidekazu Hiroaki
Journal:  Int J Mol Sci       Date:  2015-07-10       Impact factor: 5.923

5.  Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory.

Authors:  M Fá; D Puzzo; R Piacentini; A Staniszewski; H Zhang; M A Baltrons; D D Li Puma; I Chatterjee; J Li; F Saeed; H L Berman; C Ripoli; W Gulisano; J Gonzalez; H Tian; J A Costa; P Lopez; E Davidowitz; W H Yu; V Haroutunian; L M Brown; A Palmeri; E M Sigurdsson; K E Duff; A F Teich; L S Honig; M Sierks; J G Moe; L D'Adamio; C Grassi; N M Kanaan; P E Fraser; O Arancio
Journal:  Sci Rep       Date:  2016-01-20       Impact factor: 4.379

6.  Humanized tau antibodies promote tau uptake by human microglia without any increase of inflammation.

Authors:  Monika Zilkova; Anna Nolle; Branislav Kovacech; Eva Kontsekova; Petronela Weisova; Peter Filipcik; Rostislav Skrabana; Michal Prcina; Tomas Hromadka; Ondrej Cehlar; Gabriela Paulikova Rolkova; Denisa Maderova; Michal Novak; Norbert Zilka; Jeroen J M Hoozemans
Journal:  Acta Neuropathol Commun       Date:  2020-05-29       Impact factor: 7.801

7.  Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer's disease and frontotemporal dementia.

Authors:  Mei Ji; Xi-Xiu Xie; Dong-Qun Liu; Xiao-Lin Yu; Yue Zhang; Ling-Xiao Zhang; Shao-Wei Wang; Ya-Ru Huang; Rui-Tian Liu
Journal:  Alzheimers Res Ther       Date:  2018-06-19       Impact factor: 6.982

8.  Therapeutic antibody targeting microtubule-binding domain prevents neuronal internalization of extracellular tau via masking neuron surface proteoglycans.

Authors:  Petronela Weisová; Ondrej Cehlár; Rostislav Škrabana; Monika Žilková; Peter Filipčík; Branislav Kováčech; Michal Prčina; Ľubica Wojčiaková; Ľubica Fialová; Tomáš Smolek; Eva Kontseková; Norbert Žilka; Michal Novák
Journal:  Acta Neuropathol Commun       Date:  2019-08-07       Impact factor: 7.801

9.  Microglia display modest phagocytic capacity for extracellular tau oligomers.

Authors:  Petra Majerova; Monika Zilkova; Zuzana Kazmerova; Andrej Kovac; Kristina Paholikova; Branislav Kovacech; Norbert Zilka; Michal Novak
Journal:  J Neuroinflammation       Date:  2014-09-13       Impact factor: 8.322

10.  Expression and purification of tau protein and its frontotemporal dementia variants using a cleavable histidine tag.

Authors:  Thomas K Karikari; Alexandra Turner; Robert Stass; Leonie C Y Lee; Bethany Wilson; David A Nagel; Eric J Hill; Kevin G Moffat
Journal:  Protein Expr Purif       Date:  2016-09-20       Impact factor: 1.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.